Final answer:
Dr. Aubrey de Grey and the SENS project aim to develop therapies to combat aging, but specific timelines for availability in mice or humans are not determined from the provided information. Research on aging includes studies on reversing tissue degeneration and understanding genetic contributions to diseases like Alzheimer's. Therefore, timelines for therapies' availability are uncertain and depend on various factors.
Step-by-step explanation:
The work of Dr. Aubrey de Grey and the SENS project (Strategies for Engineered Negligible Senescence) has been focused on developing therapies to prevent and cure aging. The specific timelines for when these therapies will be available for mice and humans are not provided in the information available to me as of my knowledge cutoff in early 2023. The research on aging covers various aspects, from genetic studies that may lead to a cure for diseases like Alzheimer's to the reversal of tissue degeneration in aged telomerase-deficient mice, as described by Mariella Jaskelioff et al. in 2011. These findings are promising and may lead to human clinical trials in the future.
Dr. de Grey is known for his optimistic predictions about the timeline for these types of therapies, often suggesting that they may be available within a human generation. However, it is important to note that scientific developments often experience delays due to a myriad of factors, including technological limitations, regulatory hurdles, and funding challenges. As such, while the therapies show potential, the exact years in which these will be available for mice and subsequently humans cannot be precisely determined without current statements from de Grey or the SENS project.